Evidence map›Paper›PMID 33417208›Full record

ArticleAdvances in experimental medicine and biology2020

Zellweger Syndrome Disorders: From Severe Neonatal Disease to Atypical Adult Presentation.

David Cheillan

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. The peroxisome: an update on mysteries 3.0.Histochemistry and cell biology · 2024
    Review
  2. Review
  3. The Physiological and Pathological Role of Acyl-CoA Oxidation.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Translational pediatrics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

David CheillanInserm U1060 - CarMeN Laboratory, Lyon University, Pierre-Bénite, France. david.cheillan@chu-lyon.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zellweger syndrome disorders (ZSD) is the principal group of peroxisomal disorders characterized by a defect of peroxisome biogenesis due to mutations in one of the 13 PEX genes. The clinical spectrum is very large with a continuum from antenatal forms to adult presentation. Whereas biochemical profile in body fluids is classically used for their diagnosis, the revolution of high-throughput sequencing has extended the knowledge about these disorders. The aim of this review is to offer a large panorama on molecular basis, clinical presentation and treatment of ZSD, and to update the diagnosis strategy of these disorders in the era of next-generation sequencing (NGS).

Indexed as

Infant, Newborn, DiseasesZellweger SyndromeAdultHigh-Throughput Nucleotide SequencingHumansInfant, NewbornMutationPeroxisomesNext-generation sequencing (NGS)PeroxisomePeroxisome biogenesis disorder (PBD)PEX genesPrenatal diagnosisVery-long-chain fatty acids (VLCFAs)Zellweger syndrome disorder (ZSD)

Identifiers

PMID33417208

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.